Walleye Capital’s Aldeyra Therapeutics ALDX Stock Holding History

Walleye Capital’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,000	Closed	-$46K	–	4425
2025 Q2	$46K	Buy	+12,000	New	+$31K	﹤0.01%	4065

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Capital's ALDX Position: Q1 2026 in Review

Walleye Capital sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 18,595 shares — an estimated $96.3K sold.

Walleye Capital first reported a position in ALDX in Q2 2021 and held it in 7 quarters. The position peaked at $1.42M in Q4 2021. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Walleye Capital reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
Walleye Capital sold 18,595 Aldeyra Therapeutics shares in Q1 2026, an estimated $96.3K.
Walleye Capital first reported a position in Aldeyra Therapeutics in Q2 2021 and held it in 7 quarters.
Walleye Capital's Aldeyra Therapeutics position peaked at $1.42M in Q4 2021.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.